Figures & data
Figure 2 Mechanism of DOX-hyd-BSA NPs targeting pro-inflammatory neutrophils to induce their apoptosis for the treatment of septic inflammation. (A) The therapeutic mechanism of DOX-hyd-BSA NPs; (B) The preparation route of DOX-conjugated BSA NPs.
![Figure 2 Mechanism of DOX-hyd-BSA NPs targeting pro-inflammatory neutrophils to induce their apoptosis for the treatment of septic inflammation. (A) The therapeutic mechanism of DOX-hyd-BSA NPs; (B) The preparation route of DOX-conjugated BSA NPs.](/cms/asset/56a3d0e4-8b36-44c3-a872-2f045ba8edf6/dijn_a_12155525_f0002_c.jpg)
Figure 3 Scheme for designing IME responsive and biofunctional nanoparticles (NPs) and for targeted delivery of nanotherapeutics at the site of infection. (A) The designing strategy of intercellular adhesion molecule-1 antibodies-modified multifunctional NPs; (B) The prepared NPs showed a preferential accumulation at a site of infection by interaction with intercellular adhesion molecule-1.
![Figure 3 Scheme for designing IME responsive and biofunctional nanoparticles (NPs) and for targeted delivery of nanotherapeutics at the site of infection. (A) The designing strategy of intercellular adhesion molecule-1 antibodies-modified multifunctional NPs; (B) The prepared NPs showed a preferential accumulation at a site of infection by interaction with intercellular adhesion molecule-1.](/cms/asset/b17232f8-d549-4a5f-9ec2-da620d337c32/dijn_a_12155525_f0003_c.jpg)
Table 1 Antioxidant Nanodrug Delivery System with Potential to Alleviate Liver Injury in Sepsis
Figure 4 Preparation and efficacy assessment of PEG-HNPs for sepsis treatment.
![Figure 4 Preparation and efficacy assessment of PEG-HNPs for sepsis treatment.](/cms/asset/58a4756f-9a4a-41a2-9888-3128d4faec4d/dijn_a_12155525_f0004_c.jpg)
Table 2 Summary of Drug Delivery Nanosystems for Bacterial Translocation in SRIL